9 results
10-K
2020 FY
LABP
Landos Biopharma Inc
31 Mar 21
Annual report
5:03pm
in normal healthy volunteers will be in the first half of 2024. The normal healthy volunteer study will feature a standard single ascending dose/multiple … to initiate a Phase 1 study in normal healthy volunteers in the second half of 2022. The normal healthy volunteer study will feature a standard single
424B4
LABP
Landos Biopharma Inc
4 Feb 21
Prospectus supplement with pricing info
5:02pm
to initiate a Phase 1 study in normal healthy volunteers will be in the first half of 2024. The normal healthy volunteer study will feature a standard … in the first half of 2022, we intend to initiate a Phase 1 study in normal healthy volunteers in the second half of 2022. The normal healthy volunteer study
S-1/A
LABP
Landos Biopharma Inc
28 Jan 21
IPO registration (amended)
9:12am
volunteer study will feature a standard single ascending dose/multiple ascending dose design testing a dose range 5-fold to 10-fold greater than … . The normal healthy volunteer study will feature a standard single ascending dose/multiple ascending dose design testing a dose range 5-fold to 10-fold
S-1
07su410
13 Jan 21
IPO registration
5:07pm
DRS/A
1ics7g8z
1 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
rqt5xjgzhvsd
1 Sep 20
Draft registration statement (amended)
12:00am
DRS
4gc5ci45f1f 0sw
24 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next